07 Jan 2001

Zeel®; -P (Zeel® Tabletten) - Deutschland

Updated: 07 Jan 2001

Zeel®; -P

Arthrosis (besonders Gonarthrosis), Polyarthrosis, Spondylarthrosis, Periarthritis humeroscapularis.

Zeel®; -P Description, Presentation and Dosage

Zeel®; -P Description

Zeel®; -P Drug Class Description


Zeel®; -P Drug Description

1 Tbl. enth.: Auszug (1:10) aus Cartilago suis 0,3 µg, Auszug (1:10) aus Funiculus umbilicalis suis 0,3 µg, Auszug (1:10) aus Embryo suis 0,3 µg, Auszug (1:10) aus Placenta suis 0,3 µg, Rhus toxicodendr. 'Urtink.' 108 µg, Extr. Flor. Arnicae spir. fld. (1:1) 60 µg, Dulcamara 'Urtink.' 3 µg, Symphytum 'Urtink.' 30 µg, Sanguinaria 'Urtink.' 4,5 µg, Sulfur 'Urtink.' 5,4 µg, Hochdisperses Siliciumdioxid 3 ng, Nadid 0,03 ng, Coenzym A 0,03 ng, (±)-'alpha'-Liponsäure 0,03 ng, Natriumoxalacetat 0,03 ng. aus Placenta suis 22 ng, Rhus toxicodendr. 'Urtink.' 0,22 mg, Arnica 'Urtink.' 0,22 mg, Dulcamara 'Urtink.' 22 µg, Symphytum 'Urtink.' 22 µg, Sanguinaria 'Urtink.' 33 µg, Sulfur 'Urtink.' 39,6 µg, Nadid 0,22 ng, Coenzym A 0,22 ng, (±)-'alpha'-Liponsäure 0,22 ng, Natriumoxalacetat 0,22 ng.

Zeel®; -P Generic Name

Zeel® Tabletten

Zeel®; -P Presentation

Zeel®; -P Presentation

Zeel®; -P

Zeel®; -P Manufacturer


Related Learning Zones

Symptomatic Asthma Knowledge Centre and CME

Symptomatic Asthma Knowledge Centre and CME

Focusing on the lack of symptomatic control in patients with asthma, the new Symptomatic Asthma Learning Zone, consisting of a Disease Awareness section and an RCGP-accredited CME, is free to access for all epgonline.org members, and has been designed to provide them with the information they need to effectively manage the symptoms of their patients with asthma.

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Zeel®; -P Dosage

Zeel®; -P Adult Dosage


Zeel®; -P Child Dosage

Zeel® P Injektionslösung
Zus.: 2,2 ml enth.: Auszug (1:10) aus Cartilago suis 22 ng, Auszug (1:10) aus Funiculus umbilicalis suis 22 ng, Auszug (1:10) aus Embryo suis 22 ng, Auszug (1:10)
Weit. Bestandteile: Natriumchlorid.

Zeel®; -P Precautions, Reactions and Contraindications

Zeel®; -P Special Precautions

Related Drugs - Allergy/Clinical Immunology

Back to top